恢复期血浆治疗对重型与危重型COVID-19患者临床改善时间的影响:一项随机临床试验
这项开放标签、多中心随机临床试验在武汉7个医疗中心纳入103例实验室确诊的重型或危重型COVID-19患者,随机接受恢复期血浆联合标准治疗(52例)或单纯标准治疗(51例),计划入组200例但因故提前终止。28天内临床改善率血浆组51.9% versus 对照组43.1%,差异8.8%(95%CI -10.4%至28.0%),HR 1.40(95%CI 0.79-2.49),P=0.26,未达统计学显著。重型亚组临床改善HR 2.15(95%CI 1.07-4.32),危重型亚组HR 0.88(95%CI 0.30-2.63),交互作用P=0.17。72小时病毒PCR转阴率血浆组87.2% versus 对照组37.5%(OR 11.39,95%CI 3.91-33.18,P<0.001)。
要点
- 重型或危重型COVID-19患者加用恢复期血浆,28天内临床改善率51.9% versus 43.1%,HR 1.40(95%CI 0.79-2.49),未达统计学显著。
- 重型亚组临床改善HR 2.15(95%CI 1.07-4.32,P=0.03),危重型亚组HR 0.88(95%CI 0.30-2.63,P=0.83),交互作用P=0.17。
- 28天死亡率血浆组15.7% versus 对照组24.0%,OR 0.59(95%CI 0.22-1.59),无显著差异。
- 72小时病毒PCR转阴率血浆组87.2% versus 对照组37.5%,OR 11.39(95%CI 3.91-33.18),P<0.001。
- 血浆组2例输血后数小时内出现不良事件,经支持治疗好转。
适用人群与场景
- 实验室确诊的COVID-19成人患者,病情为重型(呼吸窘迫和/或低氧血症)或危重型(休克、器官衰竭或需机械通气)。
- 研究在武汉7个医疗中心开展,纳入时间为2020年2月14日至2020年4月1日,最终随访至2020年4月28日。
诊断标准与关键阈值
- 临床改善定义为28天内出院存活或6点疾病严重度量表评分降低2分,该量表范围从1分(出院)到6分(死亡)。
处置流程与药物剂量
- 恢复期血浆组在标准治疗基础上加用恢复期血浆,对照组仅接受标准治疗,按疾病严重程度分层。
红旗征与不能漏的情况
- 血浆组2例在输血后数小时内出现不良事件,经支持治疗好转。
研究设计与关键结果
- 开放标签、多中心随机临床试验,纳入103例重型或危重型COVID-19患者(中位年龄70岁,男性60例占58.3%),101例(98.1%)完成试验;计划入组200例,实际入组103例后提前终止。
- 28天内临床改善:血浆组51.9%(27/52) versus 对照组43.1%(22/51),差异8.8%(95%CI -10.4%至28.0%),HR 1.40(95%CI 0.79-2.49),P=0.26。
- 重型亚组28天内临床改善:血浆组91.3%(21/23) versus 对照组68.2%(15/22),HR 2.15(95%CI 1.07-4.32),P=0.03。
- 危重型亚组28天内临床改善:血浆组20.7%(6/29) versus 对照组24.1%(7/29),HR 0.88(95%CI 0.30-2.63),P=0.83;亚组交互作用P=0.17。
- 28天死亡率:血浆组15.7% versus 对照组24.0%,OR 0.59(95%CI 0.22-1.59),P=0.30。
- 28天内出院率:血浆组51.0% versus 对照组36.0%,HR 1.61(95%CI 0.88-2.95),P=0.12。
- 72小时病毒PCR转阴率:血浆组87.2% versus 对照组37.5%,OR 11.39(95%CI 3.91-33.18),P<0.001。
- 血浆组2例输血后数小时内出现不良事件,经支持治疗好转。
证据类型、等级与局限
- 证据类型:开放标签、多中心随机临床试验。
- 试验注册:中国临床试验注册中心 ChiCTR2000029757。
- 局限:试验提前终止,可能把握度不足,无法检出有临床意义的差异。
对床旁实践的改变
- 在重型或危重型COVID-19患者中,标准治疗加恢复期血浆较单纯标准治疗未显著改善28天内临床改善时间,主要终点未达统计学显著。
- 重型亚组中恢复期血浆的临床改善HR 2.15(95%CI 1.07-4.32),危重型亚组HR 0.88(95%CI 0.30-2.63),交互作用P=0.17。
- 恢复期血浆与72小时病毒PCR转阴率升高相关(87.2% versus 37.5%,OR 11.39,95%CI 3.91-33.18)。
- 作者指出,试验提前终止可能使研究把握度不足,无法检出有临床意义的差异。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Convalescent plasma is a potential therapeutic option for patients with coronavirus disease 2019 (COVID-19), but further data from randomized clinical trials are needed.
OBJECTIVE: To evaluate the efficacy and adverse effects of convalescent plasma therapy for patients with COVID-19.
DESIGN, SETTING, AND PARTICIPANTS: Open-label, multicenter, randomized clinical trial performed in 7 medical centers in Wuhan, China, from February 14, 2020, to April 1, 2020, with final follow-up April 28, 2020. The trial included 103 participants with laboratory-confirmed COVID-19 that was severe (respiratory distress and/or hypoxemia) or life-threatening (shock, organ failure, or requiring mechanical ventilation). The trial was terminated early after 103 of a planned 200 patients were enrolled.
INTERVENTION: Convalescent plasma in addition to standard treatment (n = 52) vs standard treatment alone (control) (n = 51), stratified by disease severity.
MAIN OUTCOMES AND MEASURES: Primary outcome was time to clinical improvement within 28 days, defined as patient discharged alive or reduction of 2 points on a 6-point disease severity scale (ranging from 1 [discharge] to 6 [death]). Secondary outcomes included 28-day mortality, time to discharge, and the rate of viral polymerase chain reaction (PCR) results turned from positive at baseline to negative at up to 72 hours.
RESULTS: Of 103 patients who were randomized (median age, 70 years; 60 [58.3%] male), 101 (98.1%) completed the trial. Clinical improvement occurred within 28 days in 51.9% (27/52) of the convalescent plasma group vs 43.1% (22/51) in the control group (difference, 8.8% [95% CI, -10.4% to 28.0%]; hazard ratio [HR], 1.40 [95% CI, 0.79-2.49]; P = .26). Among those with severe disease, the primary outcome occurred in 91.3% (21/23) of the convalescent plasma group vs 68.2% (15/22) of the control group (HR, 2.15 [95% CI, 1.07-4.32]; P = .03); among those with life-threatening disease the primary outcome occurred in 20.7% (6/29) of the convalescent plasma group vs 24.1% (7/29) of the control group (HR, 0.88 [95% CI, 0.30-2.63]; P = .83) (P for interaction = .17). There was no significant difference in 28-day mortality (15.7% vs 24.0%; OR, 0.59 [95% CI, 0.22-1.59]; P = .30) or time from randomization to discharge (51.0% vs 36.0% discharged by day 28; HR, 1.61 [95% CI, 0.88-2.95]; P = .12). Convalescent plasma treatment was associated with a negative conversion rate of viral PCR at 72 hours in 87.2% of the convalescent plasma group vs 37.5% of the control group (OR, 11.39 [95% CI, 3.91-33.18]; P < .001). Two patients in the convalescent plasma group experienced adverse events within hours after transfusion that improved with supportive care.
CONCLUSION AND RELEVANCE: Among patients with severe or life-threatening COVID-19, convalescent plasma therapy added to standard treatment, compared with standard treatment alone, did not result in a statistically significant improvement in time to clinical improvement within 28 days. Interpretation is limited by early termination of the trial, which may have been underpowered to detect a clinically important difference.
TRIAL REGISTRATION: Chinese Clinical Trial Registry: ChiCTR2000029757.
参考来源
- Li L, Zhang W, Hu Y, et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. JAMA. 2020. PMID: 32492084. doi:10.1001/jama.2020.10044
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。